Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

What is the purpose of this trial?

The primary objective of this study is to assess the rates of HIV-1 seroconversion in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir DF (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Gilead Sciences

Dates: 12/01/2016 - 02/28/2019

Last Updated: 02/09/2017

Study HIC#: 1608018342

Get Involved

For more information about this study, contact:
Laurie J Andrews
+1 203-785-3557
laurie.andrews@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Onyema Eberechukwu Ogbuagu

Principal Investigator

Sub-Investigators